FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, and aims at treating new growths. What is used is an effective amount of a first compound specified in (E)-N-{4-[3-chlor-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, an ester thereof, an ether thereof, carbamate or a pharmaceutically acceptable salt thereof, and a second compound specified in vinorelbine or a pharmaceutically acceptable salt thereof. There are also described a pharmaceutical combination and a product for treating new growths.
EFFECT: group of invention enables delaying cell proliferation and disease development.
23 cl, 3 ex, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2013 |
|
RU2670974C2 |
| ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE | 2009 |
|
RU2498804C2 |
| ANTI-TUMOUR COMBINATIONS MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2006 |
|
RU2451524C2 |
| ANTITUMOUR COMBINATIONS WITH MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2012 |
|
RU2632104C2 |
| TREATMENT REGIMEN FOR BREAST CANCER USING NERATINIB | 2019 |
|
RU2804713C2 |
| METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS | 2007 |
|
RU2492864C2 |
| PROCESS FOR TREATMENT OF BREAST CANCER USING NERATINIB | 2014 |
|
RU2685715C2 |
| METHOD OF TREATING GEFITINIB-RESISTANT CANCER | 2006 |
|
RU2405566C9 |
| USE OF 3-(4-AMINO-1-OXO-1, 3-DIHYDROISOINDOL-2-YL)PIPERIDINE-2,6-DIONE FOR TREATING MANTLE CELL LYMPHOMAS | 2007 |
|
RU2446804C2 |
| COMBINATION OF OZOGAMICIN INOTUZUMAB AND TORIZEL FOR TREATING CANCER | 2012 |
|
RU2607594C2 |
